The Effect of Fluorouracil Implants Regional Chemotherapy During the Surgical Treatment for Early Stage Hepatocellular Carcinoma
A Randomized, Controlled Trial of Fluorouracil Implants Regional Chemotherapy During the Surgical Treatment for Early Stage Hepatocellular Carcinoma
1 other identifier
interventional
250
1 country
1
Brief Summary
This study will assess the clinical efficacy and safety of fluorouracil implants regional chemotherapy during the surgical treatment for early-stage hepatocellular carcinoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Aug 2009
Longer than P75 for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2009
CompletedFirst Submitted
Initial submission to the registry
January 22, 2010
CompletedFirst Posted
Study publicly available on registry
January 26, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2014
CompletedJanuary 26, 2010
January 1, 2010
5 years
January 22, 2010
January 24, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To assess the clinical benefit of fluorouracil implants regional chemotherapy during the radical resection in early stage hepatocellular carcinoma patients. The primary endpoint is disease-free survival (DFS).
1, 2, and 3 years
Secondary Outcomes (3)
Quality of Life
from baseline to the last visit
Incidence Rate of Complications
1, 2, and 3 years
Adverse Events
from the beginning of treatment to the end of study
Study Arms (2)
Radical resection + Fluorouracil Implants
EXPERIMENTALRadical resection
ACTIVE COMPARATORInterventions
Radical resection of hepatocellular carcinoma
Implanted during the surgical treatment
Eligibility Criteria
You may qualify if:
- Histological diagnosis of stage I hepatocellular carcinoma
- Child-Pugh class A, B
- Radical resection is feasible
- Patients with adequate renal, hepatic, and hematologic function
- Written informed consent
You may not qualify if:
- Allergic to chemotherapy drugs
- No measurable lesion
- Receive chemotherapy, radiotherapy or biotherapy within 30 days prior to enrollment
- Evidence of serious infection
- Renal or hepatic dysfunction, significant cardiovascular disease
- Pregnant or lactating women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Eastern Hepatobiliary Surgery Hospital
Shanghai, 200438, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Shuqun Cheng, MD
Eastern Hepatobiliary Surgery Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
January 22, 2010
First Posted
January 26, 2010
Study Start
August 1, 2009
Primary Completion
August 1, 2014
Study Completion
August 1, 2014
Last Updated
January 26, 2010
Record last verified: 2010-01